摘要
非肌层浸润性膀胱癌（NMIBC）指局限于黏膜和黏膜下的膀胱恶性肿瘤.NMIBC具有高复发性,且有可能进展为肌层浸润性膀胱癌,术后的辅助腔内灌注治疗可使部分患者获益.目前临床上用于膀胱灌注的药物很多,但寻找出更加有效、安全的新型膀胱灌注药物一直是研究热点.
Non-muscle invasive bladder cancer （NMIBC） represents the malignant tumor of urinary bladder which is limited to mucosa and submucosal.NMIBC has high recurrence,and can progress to muscle invasive bladder cancer.Adjuvant intracavitary perfusion is beneficial for patients after surgery.There are many drugs for intravesical instillation in clinic.However,the new bladder perfusion drug which is safer and more effective,is always a research hotspot.
出处
《肿瘤研究与临床》
CAS
2014年第12期857-859,共3页
Cancer Research and Clinic
基金
湖南省科技计划（2013FJ6008）
关键词
膀胱肿瘤
非肌层浸润性
膀胱灌注
新型药物
Bladder neoplasms,non muscle invasive
Bladder perfusion
New drugs
